ZA991572B - New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide. - Google Patents

New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.

Info

Publication number
ZA991572B
ZA991572B ZA9901572A ZA991572A ZA991572B ZA 991572 B ZA991572 B ZA 991572B ZA 9901572 A ZA9901572 A ZA 9901572A ZA 991572 A ZA991572 A ZA 991572A ZA 991572 B ZA991572 B ZA 991572B
Authority
ZA
South Africa
Prior art keywords
methyl
methylcarbamoyl
phenylethyl
naphthyl
amide
Prior art date
Application number
ZA9901572A
Other languages
English (en)
Inventor
Claus Ulrich Jessen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA991572B publication Critical patent/ZA991572B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9901572A 1998-03-03 1999-02-26 New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide. ZA991572B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK28298 1998-03-03

Publications (1)

Publication Number Publication Date
ZA991572B true ZA991572B (en) 1999-09-03

Family

ID=8091813

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901572A ZA991572B (en) 1998-03-03 1999-02-26 New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.

Country Status (15)

Country Link
EP (1) EP1060190B1 (xx)
JP (1) JP2002505340A (xx)
KR (1) KR20010041533A (xx)
CN (1) CN1291994A (xx)
AT (1) ATE254632T1 (xx)
AU (1) AU3247899A (xx)
BR (1) BR9908399A (xx)
CA (1) CA2322051A1 (xx)
DE (1) DE69912930D1 (xx)
HU (1) HUP0100998A3 (xx)
IL (1) IL137353A0 (xx)
PL (1) PL342706A1 (xx)
TW (1) TW538047B (xx)
WO (1) WO1999045029A1 (xx)
ZA (1) ZA991572B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
JP5767643B2 (ja) 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド 1’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
AU2016205311B2 (en) 2015-01-08 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
ES2961460T3 (es) 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノヌクレオシドを調製する方法
AU2021251689A1 (en) 2020-04-06 2022-11-17 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
WO2021262826A2 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TW202228722A (zh) 2020-08-27 2022-08-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869974B1 (en) * 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties

Also Published As

Publication number Publication date
EP1060190A1 (en) 2000-12-20
CA2322051A1 (en) 1999-09-10
HUP0100998A2 (hu) 2001-08-28
BR9908399A (pt) 2000-10-31
EP1060190B1 (en) 2003-11-19
AU3247899A (en) 1999-09-20
IL137353A0 (en) 2001-07-24
JP2002505340A (ja) 2002-02-19
HUP0100998A3 (en) 2001-12-28
PL342706A1 (en) 2001-07-02
DE69912930D1 (de) 2003-12-24
WO1999045029A1 (en) 1999-09-10
ATE254632T1 (de) 2003-12-15
KR20010041533A (ko) 2001-05-25
TW538047B (en) 2003-06-21
CN1291994A (zh) 2001-04-18

Similar Documents

Publication Publication Date Title
ZA991572B (en) New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.
RS82003A (xx) Amidi antranilne kiseline, postupak za njihovu proizvodnju, njihova primena u svojstvu antiaritmijskih sredstava kao i farmaceutski preparati koji sadrže ta jedinjenja
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
WO2000055125A3 (en) N-cyanomethyl amides as protease inhibitors
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
AU2003245804A1 (en) Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
IL149525A0 (en) Use of hydroxyflavanones for masking bitter taste
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
PL309721A1 (en) Pharmaceutical composition containing fluoxetin hydrochloride
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
WO2002058692A3 (fr) Composition halogenee de hypohalites avec n-chloramine taurine, procede de preparation et ses utilisations
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
AU2001267886A1 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
DE60119976D1 (en) Thixotropes nasenspray
HUP0202324A2 (hu) Prukaloprid orális oldat
HRP20050580A2 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
WO2003017762A3 (de) Fungizide wirkstoffkombinationen
CA2429793A1 (en) Interferon therapeutic effect enhancer
MY122588A (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
PL352532A1 (en) New analogues: 2', 3'-dideoxy-3'fluorothymidyne active against the hiv-1 and hiv-2 viruses, the method of their manufacture, and pharmaceuticals containing them
AU3147800A (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
AU3147900A (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
TW200631600A (en) Hair fitness/body improving agent and hair cosmetic